Sarepta Therapeutics

Organisation

Trials

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
Phase 4, Recruiting, 20 people, 21 Apr 2026
NCT01396239
Phase 2, Completed, 12 people, 18 Jul 2011

Sources: clinicaltrials.gov

Named in competing interests

Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk
Grants or research support, 3 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov